Table 3.

Results of Cox regression analysis of survival predictors in 126 patients with BM.

Variable	Univariate analysis		Multivariate analysis
	HR (95% CI)	p Value	HR (95% CI)	p Value
ER- and PR- vs ER or PR+	1.477 (1.006–2.168)	0.047	1.656 (1.107–2.478)	0.014*
HER2- vs HER2+	1.625 (1.125–2.347)	0.010	1.608 (1.099–2.352)	0.014*
Triple negative vs others	1.758 (1.194–2.588)	0.004	1.692 (1.137–2.518)	0.010*
Age ≥ 45 yrs vs < 45 yrs	1.815 (1.245–2.647)	0.002	1.700 (1.155–2.504)	0.007†
Disease free interval: < 24 months vs ≥ 24 months	1.857 (1.258–2.740)	0.002	1.379 (0.897–2.119)	0.143†
Interval from recurrence to BM: < 12 months vs ≥ 12 months	0.688 (0.478–0.988)	0.043	0.702 (0.478–1.031)	0.071†
Number of metastatic sites: ≥ 3 vs < 3	1.710 (1.155–2.532)	0.007	1.769 (1.141–2.743)	0.011†
Leptomeningeal disease: presence vs absence	2.069 (1.153–3.713)	0.015	2.865 (1.506–5.450)	0.001†

Abbreviations: BM, brain metastasis; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; HR, hazard ratio; PR, progesterone receptor.

*Variables regarding triple receptor status were separately analyzed adjusting for other variables (age, disease free interval, interval from recurrence to BM, number of metastatic sites, leptomeningeal disease).

†Each variable other than triple receptor status was adjusted with triple-negative vs others.